BIOT

Biotech Acquisition Company Announces Liquidation

Retrieved on: 
Thursday, February 2, 2023
Bank account, Beneficial, Trust, Finance Secretary (India), Interest on Lawyer Trust Accounts, Articles of association, BIOT, Security (finance)

New York, New York, Feb. 01, 2023 (GLOBE NEWSWIRE) --  Biotech Acquisition Company (the “Company”) (Nasdaq: BIOT), announced today that it will not implement the extension of the time period the Company has to complete an initial business combination as approved by its shareholders at an extraordinary general meeting of shareholders held on January 19, 2023 as a result of the investor being unable to deposit the requisite funds into the Company's trust account ("Trust Account") for the extension.

Key Points: 
  • New York, New York, Feb. 01, 2023 (GLOBE NEWSWIRE) --  Biotech Acquisition Company (the “Company”) (Nasdaq: BIOT), announced today that it will not implement the extension of the time period the Company has to complete an initial business combination as approved by its shareholders at an extraordinary general meeting of shareholders held on January 19, 2023 as a result of the investor being unable to deposit the requisite funds into the Company's trust account ("Trust Account") for the extension.
  • In order to provide for the disbursement of funds from the Trust account, the Company will instruct the trustee of the Trust Account to take all necessary actions to liquidate the securities held in the Trust Account.
  • The proceeds of the Trust Account will be held in a non-interest bearing account while awaiting disbursement to the holders of the Public Shares.
  • Record holders will receive their pro rata portion of the proceeds of the Trust Account by delivering their Public Shares to Continental Stock Transfer & Trust Company, the Company’s transfer agent.

Biotech Acquisition Company Announces Submission of Prospectus Supplement to the Proxy Statement/Prospectus to The Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.

Retrieved on: 
Tuesday, May 24, 2022
Aggregation, Risk, Form, Company, BIOT, U.S. Securities and Exchange Commission, Multimedia, Transaction, NASDAQ, SEC filing, Therapy, Liver, Food and Drug Administration Amendments Act of 2007, Cayman Islands, COVID-19, Failure, Neurodegeneration, Securities Act of 1933, Probability, PIPE, Forward-looking statement, Proxy, Sale, Lung, LinkedIn, Acquisition, SEC, Prospectus, CA, BAC, Security (finance), Audit, Bank, Nasdaq, Blade, Target

333-263577), relating to its previously announced proposed business combination with Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical company based in South San Francisco, CA.

Key Points: 
  • 333-263577), relating to its previously announced proposed business combination with Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical company based in South San Francisco, CA.
  • Biotech Acquisition Company raised $230 million in its initial public offering in January 2021.
  • Blade Therapeutics, Inc. is a biopharmaceutical company focused on developing cutting-edge treatments for debilitating, incurable fibrotic and neurodegenerative diseases that impact millions of people worldwide.
  • This press release relates to a proposed business combination between BAC and Blade (the "Transaction").

Biotech Acquisition Company Announces Filing of First Amendment to Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.

Retrieved on: 
Monday, April 4, 2022
Company, Risk, Therapy, Proxy, LinkedIn, NASDAQ, Sale, Lung, Form, Transaction, Cayman Islands, Forward-looking statement, Multimedia, Neurodegeneration, Liver, SEC, Probability, Aggregation, BAC, PIPE, Failure, Prospectus, U.S. Securities and Exchange Commission, Securities Act of 1933, CA, COVID-19, BIOT, Bristol Myers Squibb, Acquisition, Pharmaceutical industry, Security (finance), Bank, Blade, Nasdaq, Target

These documents contain important information about BAC, Blade and the proposed business combination.

Key Points: 
  • These documents contain important information about BAC, Blade and the proposed business combination.
  • The registration statement has not yet become effective and the information contained therein and in the preliminary proxy statement/prospectus is subject to change.
  • Biotech Acquisition Company raised $230 million in its initial public offering in January 2021.
  • The Class A ordinary shares and warrants of BAC trade on the Nasdaq Capital Market under the symbols "BIOT" and "BIOTW," respectively.

Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package

Retrieved on: 
Monday, April 4, 2022
Research, Mental Health, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Risk, Therapy, Fibrosis, Biomarker, Cayman Islands, Neurodegeneration, Liver, SEC, Probability, CEO, IPF, Knowledge, Securities Act of 1933, Matrix, Business architecture, BIOT, Autotaxin, Disease, Bristol Myers Squibb, Proxy, Sale, Trial of the century, Kidney, Myofibroblast, Vital capacity, Aggregation, NASH, Combined, NASDAQ, Lung, Form, Investment, Transaction, Forward-looking statement, Mortality, LPA, BAC, Failure, Prospectus, POC, FDA, Interstitial lung disease, Patient, Company, LinkedIn, Institute of Liver and Biliary Sciences, HIV disease progression rates, PIPE, Safety, COVID-19, Acquisition, Pharmaceutical industry, Financial services, Security (finance), Audit, Risk management, Nasdaq, Blade, Target, BLADE THERAPEUTICS, BIOTECH ACQUISITION COMPANY

The FDA response letter outlined requirements for a proposed phase 2 PoC/dose ranging study for use of cudetaxestat in patients with IPF.

Key Points: 
  • The FDA response letter outlined requirements for a proposed phase 2 PoC/dose ranging study for use of cudetaxestat in patients with IPF.
  • We are pleased with the guidance provided by the FDA, said Wendye Robbins, M.D., president and CEO of Blade.
  • Available data from completed phase 1 studies in healthy volunteers showed that cudetaxestat was well tolerated with a demonstrated pharmacokinetic/pharmacodynamic correlation and biomarker activity.
  • Cudetaxestat is an investigational medicine that is not approved for commercial use by the FDA or any other regulatory authority.

Blade Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Monday, March 7, 2022
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Risk, Failure, Cayman Islands, BIOT, Fibrosis, HIV disease progression rates, Investment, Interstitial lung disease, Forward-looking statement, Matrix, Neurodegeneration, Disease, Myofibroblast, Prospectus, LinkedIn, Combined, Therapy, SEC, Bristol Myers Squibb, Blade, BAC, Company, COVID-19, Aggregation, Institute of Liver and Biliary Sciences, Form, Securities Act of 1933, Conference, NASH, CEO, Acquisition, Transaction, IPF, PIPE, Business architecture, Lung, Sale, Liver, Kidney, Mortality, LPA, Probability, Proxy, NASDAQ, Pharmaceutical industry, Financial services, Security (finance), Audit, Risk management, Target, Nasdaq, Blade Therapeutics, Biotech Acquisition Company, Blade Therapeutics, Biotech Acquisition Company, BLADE THERAPEUTICS, BIOTECH ACQUISITION COMPANY

Blade Therapeutics, Inc., a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced that Wendye Robbins, M.D., president and CEO, will present at two investor conferences in March.

Key Points: 
  • Blade Therapeutics, Inc., a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced that Wendye Robbins, M.D., president and CEO, will present at two investor conferences in March.
  • ET, in Miami
    Blade Therapeutics, Inc. is a biopharmaceutical company focused on developing cutting-edge treatments for debilitating, incurable fibrotic and neurodegenerative diseases that impact millions of people worldwide.
  • Upon the closing of the transaction, the combined company will be renamed Blade Biotherapeutics, Inc., and is expected to be listed on Nasdaq under the symbol BBTX.
  • PIPE financing is anchored by leading institutional investors, including Deerfield Management, Pfizer Ventures, Bristol Myers Squibb, MPM Capital and Osage University Partners.

Biotage Awarded Gold Sustainability Medal by EcoVadis

Retrieved on: 
Thursday, February 24, 2022
Health, Food safety, BIOT, Sustainable procurement, Water, Gold, Group, Ethics, Organization, Environment, Heart, Labour, Nasdaq Stockholm, Science, Gold medal, Drug discovery, Human, Capital, Solution, CEO, Human rights, Fine chemical, Pyrosequencing

As part of HumanKind Unlimited comes a commitment to sustainability at every level within Biotage and within every customer relationship.

Key Points: 
  • As part of HumanKind Unlimited comes a commitment to sustainability at every level within Biotage and within every customer relationship.
  • EcoVadis, a leading producer of supplier sustainability ratings, recently recognised this commitment by awarding Biotage the Gold Medal in sustainability, after a thorough audit of Biotage's performance with respect to the Environment, Labor & Human Rights, Ethics and Sustainable Procurement.
  • The gold Medal rating places Biotage in the top 5% of global suppliers across all industries.
  • Biotage is contributing to sustainable science with the goal to make the world healthier, greener and cleaner HumanKind Unlimited.

Blade Therapeutics Announces Successful Completion of Phase 1 Clinical Study that Evaluated Co-Administration of Cudetaxestat with Either of Two Approved Therapies for Idiopathic Pulmonary Fibrosis

Retrieved on: 
Wednesday, January 12, 2022
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Neurodegeneration, Medicine, Patient, Lung, Autotaxin, Mortality, Kidney, LinkedIn, Liver, Aggregation, LPA, Myofibroblast, Disease, Adult, Interstitial lung disease, NASDAQ, Institute of Liver and Biliary Sciences, CEO, HIV disease progression rates, Volunteering, Trial of the century, BIOT, NASH, Fibrosis, Therapy, Pharmacokinetics, IPF, Matrix, FDA, Acquisition, Pharmaceutical industry, Blade

There is a huge unmet need for new antifibrotic therapies which can complement current treatments and provide greater benefit for patients.

Key Points: 
  • There is a huge unmet need for new antifibrotic therapies which can complement current treatments and provide greater benefit for patients.
  • This phase 1 study of cudetaxestat provides a clear path to proceed into a phase 2 study that addresses this need for novel therapeutics that may be administered together with current anti-fibrotic drugs.
  • We look forward to discussing these data with regulatory authorities as we proceed toward the next phase of clinical development for cudetaxestat.
  • The company plans to start a phase 2 clinical study of cudetaxestat in patients with IPF in the second quarter of 2022.

Biotage moves to the large cap segment

Retrieved on: 
Monday, January 3, 2022
Pyrosequencing, Nasdaq Stockholm, CEO, Group, Science, Organization, Food safety, Capital, Water, BIOT, Drug discovery, Industrial design, Food industry, Fine chemical

UPPSALA, Sweden, Jan. 3, 2022 /PRNewswire/ -- As of today January 3, 2022, Biotage is included in Nasdaq Stockholm's Large Cap segment.

Key Points: 
  • UPPSALA, Sweden, Jan. 3, 2022 /PRNewswire/ -- As of today January 3, 2022, Biotage is included in Nasdaq Stockholm's Large Cap segment.
  • The Large Cap segment includes companies with a market capitalization of more than EUR 1 billion.
  • "Biotage continues to create value for our customers, owners and other interested parties and we consider the move to the Large Cap segment as yet another quality label and confirmation of that.
  • Biotage's share (BIOT) is listed in the Large Cap segment on the NASDAQ Stockholm.

New composition of Biotage Nomination Committee

Retrieved on: 
Monday, December 13, 2021
Ownership, Board, Annual general meeting, Water, Letter, Committee, Capital, Nasdaq Stockholm, Food safety, Person, Annual, Director, Nomination, Science, Group, Organization, BIOT, Drug discovery, Pyrosequencing

The members of the Nominations Committee are:

Key Points: 
  • The members of the Nominations Committee are:
    Joachim Spetz, appointed by Swedbank Robur Fonder, chairman
    Shareholders wishing to submit a proposal to the Nomination Committee may do so by sending e-mail to the Chairman of the Board of Directors of Biotage AB at: [email protected] .
  • Proposals should, in order to be timely assessed by the Nomination Committee, be submitted no later than seven weeks in advance of the meeting.
  • The Annual General Meeting 2022 in Biotage will be held on Thursday, April 28, 2022 at 4:00pm CET in Uppsala.
  • Biotage is contributing to sustainable science with the goal to make the world healthier, greener and cleaner HumanKind Unlimited.

Blade Therapeutics Announces Positive Topline Data from Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis

Retrieved on: 
Tuesday, November 30, 2021
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Patient, Lung, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CEO, Fibrosis, LPA, Myofibroblast, Interstitial lung disease, Acquisition, Institute of Liver and Biliary Sciences, Plasma, Kidney, Pharmacokinetics, Disease, CYP450, Neurodegeneration, BIOT, IPF, Systemic scleroderma, NASH, HIV disease progression rates, Matrix, FDA, Mortality, Therapy, LinkedIn, Enzyme, NASDAQ, Scleroderma, Food, Liver, Autotaxin, Aggregation, Pharmaceutical industry

Blade Therapeutics, Inc. (Blade), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced positive topline data from a phase 1 drug-drug interaction clinical study of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF.

Key Points: 
  • Blade Therapeutics, Inc. (Blade), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced positive topline data from a phase 1 drug-drug interaction clinical study of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF.
  • Cudetaxestat demonstrated a favorable safety and tolerability profile with no severe adverse events or drop-outs due to adverse events.
  • This study continues the momentum of our development program and supports advancing cudetaxestat in the anticipated patient populations.
  • Blade remains on track with plans to initiate a phase 2 study of cudetaxestat in patients with IPF in the first half of 2022.